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Phase 1/2 study of weekly carﬁlzomib, cyclophosphamide,
dexamethasone in newly diagnosed transplant-ineligible
myeloma
S Bringhen1, M D’Agostino1, L De Paoli2, V Montefusco3, AM Liberati4, P Galieni5, S Grammatico6, VE Muccio1, F Esma1, C De Angelis4,
P Musto7, S Ballanti8, M Ofﬁdani9, MT Petrucci6, G Gaidano2, P Corradini10, A Palumbo1,12, P Sonneveld11 and M Boccadoro1
This multicentre, open-label phase 1/2 trial determined safety and efﬁcacy of weekly carﬁlzomib plus cyclophosphamide–
dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾ 65 years or transplant ineligible. Patients
received wKCyd for up to nine 28-day cycles, followed by maintenance with carﬁlzomib until progression/intolerance. The phase 1
portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carﬁlzomib: 12 patients received
wKCyd with carﬁlzomib doses of 45, 56 and 70 mg/m2. The recommended phase 2 dose was established at 70 mg/m2 and 54
patients (phase 1 and 2) received weekly carﬁlzomib 70 mg/m2: 85% of them achieved ⩾partial response (PR), 66% ⩾ very good PR,
30%⩾ near-complete response (CR) and 15% CR. Responses improved in 40 patients who started maintenance: 98% achieved ⩾ PR,
including 29% CR and 10% stringent CR. After a median follow-up of 18 months, the 2-year progression-free survival and overall
survival rates were 53.2% and 81%, respectively. The most frequent grade 3–5 toxicities were neutropenia (22%) and
cardiopulmonary adverse events (9%). This is the ﬁrst study of weekly carﬁlzomib plus an alkylating agent in elderly patients with
NDMM. wKCyd was effective, with an acceptable risk/beneﬁt ratio, and thus can be a valid option in this setting.
Leukemia (2018) 32, 979–985; doi:10.1038/leu.2017.327
INTRODUCTION
In the last decade, the increased use of novel agents as initial
therapy of multiple myeloma (MM) signiﬁcantly improved overall
survival (OS) in patients ineligible for autologous transplantation.1 In
Europe, bortezomib–melphalan–prednisone (VMP) and melphalan–
prednisone–thalidomide combinations are considered standards of
care in elderly patients ineligible for autologous stem cell
transplantation.2,3 Dose-limiting haematological toxicity from mel-
phalan and peripheral neuropathy from bortezomib or thalidomide
limit their optimal use.4,5 Better tolerated alkylating agents, such as
cyclophosphamide, which lack the cumulative haematological
toxicity of melphalan, have been used successfully in combination
with dexamethasone and either thalidomide6 or bortezomib7 in
elderly newly diagnosed MM (NDMM) patients. Recently, based on
the results of MM020 trial, a new standard of care with no alkylating
agent has been introduced for the treatment of elderly patients
with NDMM. Indeed, that study prospectively compared outcomes
of melphalan-prednisone-thalidomide versus lenalidomide and
low-dose dexamethasone, and found that treatment with lenalido-
mide and dexamethasone until disease progression improved
progression-free survival (PFS) and OS compared with
melphalan-prednisone-thalidomide.8
Carﬁlzomib, a novel and selective proteasome inhibitor,
received accelerated approval in the United States in 2012
for the treatment of patients with relapsed and refractory MM. It
is approved in the United States and Europe when used
in combination with dexamethasone or lenalidomide plus
dexamethasone for patients with relapsed MM (one to three
prior lines of therapy).9 Under the initial approvals, carﬁlzomib is
administered as a 10 min infusion on a twice-weekly
dosing schedule, with a starting dose of 20 mg/m2 on cycle 1 days
1 and 2, and stepped up to a target dose of 27 mg/m2 thereafter.
Prolonged infusion over 30 min has been assessed in clinical
studies showing that higher carﬁlzomib doses (56 mg/m2) in
combination with dexamethasone were safe and effective.10,11
These ﬁndings were conﬁrmed with the results of the randomized
phase 3 ENDEAVOR trial (RandomizEd, opeN Label, Phase 3
Study of carﬁlzomib plus DExamethAsone Vs bortezomib
plus DexamethasOne in Patients With Relapsed Multiple
Myeloma; NCT01568866) comparing carﬁlzomib plus dexametha-
sone versus bortezomib plus dexamethasone in relapsed/refrac-
tory MM, which supported the approval of twice-weekly
carﬁlzomib (at 56 mg/m2) with dexamethasone for patients with
relapsed MM.12
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Twice-weekly intravenous administration of anti-myeloma
therapy can be burdensome for patients, especially for those
who are elderly, suffer from myeloma-related symptoms, or who
live far from the clinic. Based on results from studies showing
that once-weekly bortezomib has similar efﬁcacy and a better
safety proﬁle compared with the conventional twice-weekly
administration,13 and to follow up on the CHAMPION-1 study
evaluating weekly carﬁlzomib plus dexamethasone in the relapse
setting,14 we aimed to evaluate efﬁcacy and tolerability of once-
weekly carﬁlzomib plus cyclophosphamide and dexamethasone
(wKCyd) in NDMM elderly patients. We previously showed that
treatment with twice-weekly carﬁlzomib in combination with
cyclophosphamide-dexamethasone (KCyd) was highly effective
and well tolerated in elderly NDMM patients. Responses were
rapid and deep, and showed improvement over time. Forty-nine
percent of patients achieved ⩾ near-complete response (nCR) and
20% of patients achieved a stringent CR (sCR). After a median
follow-up of 18 months, the 2-year PFS rate was 76%. Severe
haematological adverse events (AEs) occurred in o20% of
patients and non-haematological AEs occurred in o10% of
patients, with a low (18%) rate of discontinuation.15 Given the
improved haematological safety proﬁle of cyclophosphamide and
the previous encouraging results with KCyd,15 we conducted a
phase 1/2 study to determine the maximum tolerated dose (MTD)
and evaluated the safety and efﬁcacy of once-weekly wKCyd in
elderly NDMM patients. We report the safety and efﬁcacy results of
the trial herein.
PATIENTS AND METHODS
Patients
Patients with symptomatic NDMM, who were aged ⩾ 65 years or ineligible
for autologous transplantation were included in the study. Further
eligibility criteria included measurable disease, Eastern Cooperative
Oncology Group performance status ⩽ 2, creatinine clearance ⩾ 15 ml/
min, platelet count ⩾ 50 × 109/l (⩾30 × 109/l if myeloma involvement in the
bone marrow was 450%) and absolute neutrophil count of ⩾ 1 × 109/l
without the use of growth factors. Patients were excluded from the study if
they had non-secretory MM (unless serum-free light chains were present
and the ratio was abnormal, namely o0.26 or 41.65), grade 42
peripheral neuropathy and active infection.16 In addition, per protocol,
patients had to undergo echocardiogram (ECHO) and electrocardiogram,
and were excluded from the trial if they had left ventricular ejection
fraction o40% evaluated with two-dimensional transthoracic ECHO (or
Multigated Acquisition Scan if ECHO was not available), myocardial
infarction or unstable angina ⩽ 4 months before enrolment, uncontrolled
angina, history of severe coronary artery disease, or electrocardiographic
evidence of acute ischaemia or grade 3 conduction system abnormalities
unless the subject had a pacemaker, uncontrolled hypertension, uncon-
trolled congestive heart failure or uncontrolled diabetes within 14 days
before enrolment.
All patients gave written informed consent to participate in the study,
which had been approved by the institutional ethics committees. The
study was conducted in accordance with the Declaration of Helsinki and
the principles of Good Clinical Practice. The study is registered at
Clinicaltrials.gov NCTNCT01857115.
Study design and treatment
This multicentre, non-randomized, open-label, dose-escalation phase 1/2
study determined the safety and efﬁcacy of wKCyd in NDMM patients. The
primary objective of the phase 1 portion was to determine the MTD of
once-weekly carﬁlzomib with cyclophosphamide and dexamethasone. The
primary objective of the phase 2 portion was to determine the overall
response rate. Secondary endpoints included response rates, PFS, time to
progression, duration of response, OS, time to next therapy, subgroup
analyses of prognostic factors, the evaluation of the effect of maintenance
on PFS and OS, and the relationship between responses and PFS in
responding and non-responding patients.
All patients received oral cyclophosphamide 300 mg/m2 on days 1, 8
and 15, and oral dexamethasone 40 mg on days 1, 8, 15 and 22.
Carﬁlzomib was administered as a 30 min, intravenous infusion on days 1,
8 and 15 of a 28-day cycle. In the phase 1 dose-escalation portion, patients
received carﬁlzomib at 20 mg/m2 on cycle 1, day 1; subsequent doses were
escalated in a standard 3+3 dose-escalation scheme at 45, 56 and 70 mg/
m2 to determine the MTD. In the phase 2 portion, patients received
carﬁlzomib at the MTD with the same schedule as in the phase 1 portion
(Supplementary Figure S1). Treatment was given every 28 days for nine
cycles. Patients then received maintenance therapy with carﬁlzomib at the
MTD on days 1, 15 every 28 days until progression or intolerance.
Intravenous hydration (250 ml) before and after dose administration was
given during cycle 1 and at the investigator’s discretion thereafter.
Any toxicity requiring a dose reduction within cycle 1, inability to receive
day-1 dose of cycle 2 due to drug-related toxicity persisting from cycle 1,
including cardiovascular events, represents a dose-limiting toxicity (DLT). In
addition, regardless of dose modiﬁcation or treatment delay, among
haematologic toxicities, grade 4 neutropenia or thrombocytopenia lasting
for ⩾ 7 days, febrile neutropenia, grade 3–4 thrombocytopenia associated
with bleeding are considered DLTs. Among non-haematologic toxicities,
grade ⩾ 3 nausea, vomiting or diarrhoea despite maximal antiemetic/
antidiarrhoeal therapy, grade 4 fatigue lasting for ⩾ 7 days are DLTs, as well
as the ﬁrst occurrence of grade ⩾ 2 neuropathy with pain in the ﬁrst
treatment cycle.
Assessment
For all patients receiving at ⩾ 1 dose of any study drug, toxicity was
assessed according to the National Cancer Institute Common Terminology
Criteria, version 4.0.17 Response was assessed according to the Interna-
tional Myeloma Working Group criteria18 with the addition of nCR, deﬁned
as the absence of monoclonal component in the serum and/or urine with
immunoﬁxation positive. The response assessments were undertaken at
the beginning of each treatment cycle (Supplementary Figure S1) during
induction and every three cycles during maintenance. Fluorescence in situ
hybridization was used to detect t(4:14), t(11:14), t(14;16), del13 and del
(17p). Bone marrow samples were collected at study entry and
investigations were performed at one central laboratory. For the present
analysis, the cutoff value of 60% for the proportion of plasma cells with del
(17p) was used, according to the recommendation from the International
Myeloma Workshop Consensus panel 2.19
Statistical analysis
For the sample size of the phase 1 portion of the study, each wKCyd dose
level cohort could have a minimum of three patients and a maximum of six
patients. Therefore, a maximum of 18 patients could be recruited in the
phase 1. The sample size of the phase 2 portion of the study was estimated
according two-stage Simon optimal design, with early stopping rules in
case of efﬁcacy lower than a predeﬁned uninteresting response rate. We
assumed an overall response rate p0 of 0.40, under which further study of
the wKCyd combination would not be justiﬁed, and an overall response
rate p1 of 0.60, which could justify additional investigation of this
combination. Probability of type I (α) error was set to be 0.05 and type II (β)
error 0.20. In the ﬁrst stage of phase 2, 16 patients had to be accrued. If
seven or less responses had been observed, the trial would have been
stopped for futility. Otherwise, 30 additional patients would have been
accrued in the second stage: if 23 or fewer responses had been observed
by the end of this stage, no further investigation would have been
warranted. With this design, the expected number of enrolled patients was
46 and the probability of early termination was 71.6%. Assuming ~ 10% of
patients lost to follow-up, an adequate sample size was 53 patients.
Response rates and safety were analysed in patients who received ⩾ 1
dose of study treatment. Time-to-event endpoints were determined using
the intent-to-treat population. The Kaplan–Meier product limit method was
used to estimate survivorship functions for time-to-event endpoints. Cox
proportional hazards regression was used to assess the effects of
demographic and prognostic variables on relative treatment differences.
Continuous and categorical data were summarized using descriptive
statistics. SAS System version 8.2 system (SAS Institute Inc., Cary, NC, USA)
was used.
Role of the funding source
The study was sponsored by Hovon Foundation and co-sponsored in Italy
by Fo.Ne.Sa. Onlus and it was supported by funding from Onyx
Pharmaceuticals, Inc. (South San Francisco, CA, USA) ﬁrst and Amgen
(Thousand Oaks, CA, USA) afterwards. The funders had no role in the
collection, analysis or interpretation of data. All authors had full access to
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all data in the study and had ﬁnal responsibility for the decision to submit
for publication.
RESULTS
Patients
Patients were enrolled from 10 April 2013 to 24 August 2015, in 8
centres in Italy. Twelve patients were enrolled in the phase 1 dose-
escalation portion of the study and 51 patients were enrolled in
the phase 2 portion. A total of 54 patients were treated at the
recommended phase 2 dose (RP2D) and could be assessed for
efﬁcacy and safety (Supplementary Figure S2). Baseline demo-
graphics and disease characteristics for patients enrolled in all
study phases are listed in Table 1. Median age of all patients was
72 years (interquartile range 69–74); the median left ventricular
ejection fraction was 60% (range 55–75); 14 patients (22%) were
⩾ 75 years; 19 patients (30%) had an unfavourable chromosomal
proﬁle (the presence of t(4;14), del17p or t(14;16)) and 20 (32%)
had International Staging System stage III. All patients could be
evaluated for safety and response; the median duration of
induction treatment was nine cycles (range 1–9 cycles). At the
time of analysis, 47 patients had proceeded to maintenance
therapy, 40 at the RP2D and 7 at lower doses in the phase 1
portion of the study.
MTD deﬁnition
During phase 1, in the dose-escalation portion of the study, no
DLTs were observed in the 45 mg/m2 dose cohort, 1/6 DLT was
reported in the 56 mg/m2 dose cohort (grade 3 creatinine
increase) and no DLTs were observed in the 70 mg/m2 dose
cohort. The RP2D of once-weekly carﬁlzomib with cyclopho-
sphamide and dexamethasone was determined to be 70 mg/m2
(Supplementary Table S1).
Efﬁcacy of RP2D
Overall, among patients receiving carﬁlzomib at the MTD, 46/54
(85%) patients had at least a partial response (⩾ PR), 36/54 (66%)
patients had at least a very good PR (⩾VGPR) and 16/54 (30%)
patients had at least a ⩾ nCR (Supplementary Table S1). Depth of
response increased with prolonged treatment. At the end of four
cycles, 43/48 (90%) patients achieved ⩾ PR, including 18/48 (38%)
patients with ⩾ nCR. Among patients who completed nine cycles
of treatment, 37/40 (93%) had ⩾ PR and 18/40 (44%) had ⩾nCR.
Among patients who received maintenance, 39/40 (98%) had
⩾ PR and 22/40 (54%) had ⩾nCR, including 12/40 (29%) CR and
4/40 (10%) sCR (Table 2). The median time to achieve PR was
2.4 months, but median time to sCR was 12 months and ~50% of
patients with CR achieved CR during maintenance (Figure 1). The
quality of response impacted on long-term outcome. At 2 years,
the proportion of patients alive and in remission was 100% in
patients who achieved sCR, 60% in those who achieved VGPR or
CR and 44% in those who achieved PR. Response rates were
generally similar across patient groups according to International
Staging System stage and chromosomal proﬁle (Table 2).
After a median follow-up of 19.7 months (interquartile range
14.3–28.3), the 2-year PFS and OS rates were 53.2% and 81%,
respectively (Figure 2). The risk of progression was slightly higher
in patients with International Staging System III (hazard ratio 2.46;
95% conﬁdence interval 0·99–6.1, P= 0.05) but not with high-risk
chromosomal abnormalities. The 2-year PFS was 68% in high-risk
patients and 53% in standard-risk ones (hazard ratio 0.45; 95%
conﬁdence interval 0.12–1.7, P= 0.24).
Safety of RP2D
During induction, the most common toxicities of any grade were
anaemia (39%), thrombocytopenia (33%), neutropenia (31%),
Table 1. Patient characteristics at baseline
Characteristic Phase 1
patients N= 12
RP2D patients
N= 54
All patients
N= 63
Male, n (%) 5 (42) 22 (41) 26 (41)
Age
Median (IQR),
years
73 (68–75) 72 (69–74) 72 (69–74)
⩾ 75 years, n (%) 4 (33) 11 (20) 14 (22)
ISS stage, n (%)
I 4 (33) 20 (37) 24 (38)
II 4 (33) 16 (30) 19 (30)
III 4 (33) 18 (33) 20 (32)
Creatinine clearance, ml/min, n (%)
o30 1 (8) 3 (6) 4 (6)
30–60 4 (33) 11 (20) 14 (22)
460 7 (59) 40 (74) 45 (71)
Left ventricular ejection fraction (LVEF)
Median % (range) 60 (55–72) 60 (55–75) 60 (55–75)
Chromosomal abnormalities, n (%)
t (4;14) 0 3 (6) 3 (5)
t (14;16) 1 (8) 2 (4) 3 (5)
Del 17 3 (25) 11 (20) 14 (22)
Unfavourable
proﬁlea
3 (25) 16 (30) 19 (30)
Data missing 3 (25) 17 (31) 19 (30)
Abbreviations: IQR, interquartile range; ISS, International Staging System;
RP2D, recommended phase 2 dose. aUnfavourable proﬁle was deﬁned as
the presence of t(4;14) or t(14;16), or deletion of chromosome 17.
Table 2. Response to treatment by patient characteristics and by
treatment duration in RP2D patients
Patient subgroup n Response category, n (%)
⩾ PR ⩾ VGPR ⩾ nCR ⩾CR sCR
Overall—Inductiona 54 46 (85) 36 (66) 16 (30) 7 (13) 1 (2)
Overall—Induction
+Maintenancea
54 48 (89) 37 (69) 22 (41) 12 (22) 4 (7)
ISS stage
I 20 18 (90) 17 (85) 11 (55) 6 (30) 3 (15)
II 16 16 (100) 11 (69) 7 (44) 2 (13) 1 (6)
III 18 14 (78) 9 (50) 4 (22) 4 (22) 0
Chromosomal abnormalities
Normal/
favourable
21 17 (81) 12 (57) 6 (29) 3 (14) 0
Unfavourableb 16 16 (100) 11 (69) 7 (44) 4 (25) 2 (13)
Treatment durationc
Second cycle 50 45 (90) 36 (72) 18 (36) 7 (14) 1 (2)
Fourth cycle 48 43 (90) 36 (75) 18 (38) 7 (15) 1 (2)
Sixth cycle 44 40 (91) 36 (82) 18 (41) 7 (16) 1 (2)
Ninth cycle 40 37 (93) 34 (85) 18 (44) 7 (18) 1 (3)
Maintenance 40 39 (98) 35 (88) 22 (54) 12 (29) 4 (10)
Abbreviations: CR, complete response; ISS, International Staging System;
nCR, near-complete response; PR, partial response; RP2D, recommended
phase 2 dose; sCR, stringent complete response; VGPR, very good partial
response. aIntention-to-treat analysis: all patients enrolled at the RP2D
were evaluated. bPresence of t(4;14) or t(14;16) or deletion chromosome 17.
cPer-protocol analysis: only patients who received at least 2, 4, 6 and 9
cycles, and maintenance were evaluated.
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cardiovascular events (24%), nausea/vomiting (19%), fever (13%),
infections (13%) and fatigue (9%). Grade 3–5 haematological
toxicities included neutropenia (22%), thrombocytopenia (7%) and
anaemia (2%). The most common grade 3–5 non-haematological
AEs were cardiovascular events (9%), metabolic events (6%),
infections (7%) and renal events (4%) (Table 3).
Treatment-emergent serious AEs occurred during induction in
14 patients (26%) and included four renal failures, eight cardiac
events (three heart failures, three pulmonary oedemas, one
sudden death and one hypertension), four infections (two
pneumonias, one sepsis and one upper respiratory tract), one
reversible posterior leukoencephalopathy, one hyponatremia, one
respiratory failure, one adult respiratory distress syndrome and
one pulmonary thromboembolism. A limited number of patients
required dose modiﬁcation during induction: 12 patients (22%)
discontinued treatment owing to AEs and 5 patients (9%) required
carﬁlzomib dose reductions (Supplementary Table S2).
A total of six patients died during induction; causes of death
were disease progression (two patients) and AEs (pulmonary
thromboembolism, acute respiratory failure, pneumonia and
sudden death in one patient each) (Supplementary Table S2).
During maintenance, the most common toxicities of any grade
were anaemia (8%), thrombocytopenia (20%), neutropenia (5%),
fever (15%), hypertension (15%) and nausea/vomiting (10%). No
grade 3–5 haematological toxicities were reported. Grade 3–5
non-haematological AEs were rare and occurred in o5% of
patients, with the exception of hypertension, which was reported
in 10% and cardiovascular AEs in 5% (one heart failure and one
myocardial infarction). Treatment-emergent serious AEs occurred
during maintenance in three patients and included urinary tract
infection, heart failure and myocardial infarction.
DISCUSSION
This trial is the ﬁrst to investigate carﬁlzomib on a once-weekly
dosing schedule with cyclophosphamide and dexamethasone as
part of frontline therapy in patients over 65 years of age with
symptomatic MM. The MTD of weekly carﬁlzomib incorporated
into the wKCyd regimen was found to be 70 mg/m2. Severe
haematological AEs occurred in 26% of patients and non-
haematological AEs occurred in 35% of patients, with 22% of
discontinuation.
These results compare favourably with other studies assessing
twice weekly carﬁlzomib-based regimens as frontline therapy in
elderly patients ineligible for autologous transplantation. The rate
of haematological and non-haematological AEs were similar to, or
Figure 1. Time to response onset.
Figure 2. Treatment outcome: (a) progression-free survival and (b) overall survival in patients treated with the RP2D schedule.
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lower than, those reported in our previous study with twice
weekly carﬁlzomib at the dose of 36 mg/m2 in combination with
cyclophosphamide and dexamethasone.15 Myelosuppression
induced by cyclophosphamide was lower than the one observed
with melphalan in combination with twice-weekly carﬁlzomib and
prednisone, which led to grade 3–4 neutropenia in 38% of
patients and grade 3–4 thrombocytopenia in 28%.20 This lower
myelosuppression translated in a lower incidence of infections
(13% in our trial versus 53% in the carﬁlzomib and prednisone
trial).20 The recent results of CLARION study comparing carﬁlzomib
and prednisone with VMP showed no difference in PFS between
the two regimens.21 This is probably due to a higher incidence of
severe AEs and of toxic deaths in patients receiving carﬁlzomib
and prednisone. Cyclophosphamide may therefore represent a
valid, less toxic alternative to melphalan for elderly patients
with NDMM.
This effect has been observed even in the context of
bortezomib-based treatments with higher rates of grade 3
neutropenia (40% vs 30%, respectively) and thrombocytopenia
(37% vs 12%, respectively) in the VMP therapeutic
scheme compared with bortezomib–cyclophosphamide–
dexamethasone.7,22
Regarding the choice of the optimal upfront proteasome
inhibitor in elderly NDMM patients, a direct comparison between
wKCyd regimen and similar bortezomib-based regimens is difﬁcult
because of the heterogeneity of involved studies. However,
wKCyd compared favourably with VMP (⩾VGPR rate 69% vs
41%) and bortezomib–cyclophosphamide–dexamethasone
(⩾ VGPR rate 69% vs 41%) in terms of efﬁcacy.7,22 As for safety,
grade 3 peripheral neuropathy rate was 15% with the above-
mentioned bortezomib-based regimens, whereas it was not an
issue in the current trial. However, AEs resulting in discontinuation
of therapy were slightly more frequent with the wKCyd regimen
than with VMP and bortezomib–cyclophosphamide–dexametha-
sone (22% vs 15% vs 12%, respectively).
During induction, cardiovascular events occurred in 24% of
patients, including 9% of grade 3–5 AEs, although all patients had
a baseline left ventricular ejection fraction⩾55%. Among severe
cardiac AEs, the most frequent were heart failure and pulmonary
oedema. The rate of hypertension was 11% during induction,
limited to grade 1–2, but it increased to 15% during maintenance,
including 10% of grade 3–4. In the present study, cardiovascular
toxicity was higher compared with our previous KCyD trial with
twice-weekly carﬁlzomb at 36 mg/m2, but similar to that reported
in more recent trials in NDMM setting, such as the CLARION
study,21 as well as in relapsed/refractory multiple myeloma
patients, such as the ASPIRE and the ENDEAVOR trials.12,23 The
effect of proteasome inhibition on cardiovascular system has only
recently begun to be understood. Yet, there is some evidence,
suggesting that the ubiquitine-proteasome system must be
considered a modulator of endothelial (dys)-function by interac-
tion with several essential regulatory pathways and regulation of
endothelial-dependent contracting and vasodilation factors.
Endothelial dysfunction is accompanied by deterioration in this
balance, with progressive reduction in vasodilation factors and
with an increase in vasoconstriction mediators. Available data
suggest that short-term, non-toxic proteasome inhibitors may be
beneﬁcial, whereas higher proteasome-inhibitor doses and long-
term administration are associated with more disadvantageous
effects in the vasculature.24 These data suggested a time- and
dose-dependent effect of carﬁlzomib. For patients, especially
elderly ones, candidate to treatment with carﬁlzomib, a careful
assessment before starting treatment and monitoring during
treatment is suggested. Before starting treatment, clinicians
should evaluate medical history—to determine previous cardiac
events and cardiovascular risk factors—and perform a physical
examination to assess blood pressure (BP), valvular heart disease
and signs of heart failure. A 12-lead electrocardiogram is essential
to detect possible markers of structural heart disease including the
left ventricular damage/dysfunction, arrhythmias, evidence of
previous myocardial infarction or evidence of the left ventricular
hypertrophy. The ENDEAVOR substudy found limited utility for
serial screening with ECHO to mitigate cardiac risk.25 Nevertheless,
four recent guidelines suggest that a baseline ECHO is useful to
measure the left ventricular ejection fraction before starting
treatment.26–29 Finally, a 24 h BP monitoring (ambulatory BP
monitoring) or home BP monitoring for at least 7–14 days is
needed to look for unknown or borderline or uncontrolled
Table 3. Treatment-related adverse events during induction in RP2D
patients
Events, n (%) N= 54
Any grade Grades 3–5
Haematological
⩾ 1 Event 39 (72) 14 (26)
Neutropenia 17 (31) 12 (22)
Thrombocytopenia 18 (33) 4 (7)
Anaemia 21 (39) 1 (2)
Non-haematological
⩾1 event 50 (92) 19 (35)
Cardiac events 13 (24) 5 (9)
Hypertension 6 —
Acute pulmonary oedema 3 3
Heart failure 3 2
Arrhythmia 1 —
Vascular events 2 (4) 1 (2)
Pulmonary thromboembolism 1 1
Other 1 —
Constitutional events 16 (30) 2 (4)
Oedema 2 —
Fever 7 1
Fatigue 5 1
Other 2 —
Dermatological events 0 0
Gastrointestinal events 21 (39) 2 (4)
Constipation 4 1
Diarrhoea 4 —
Nausea/vomiting 10 —
Other 3 1
Infections events 7 (13) 4 (7)
Upper respiratory tract 4 1
Pneumonia 2 2
Sepsis 1 1
Neurological events 10 (18) 3 (6)
Insomnia 2 —
Reversible posterior
leukoencephalopathy
1 1
Mood alteration 4 1
Headache 2 1
Other 1 —
Metabolic events 10 (18) 3 (6)
AST/ALT increase 4 2
Hyperglycaemia 1 —
Hyponatriemia 1 1
Hyperkaliemia 1 —
Renal events 6 (11) 2 (4)
Acute renal failure 3 1
Chronic renal failure 1 —
Creatinine increase 1 1
Other 1 —
Respiratory events 4 (7) 1 (2)
Dyspnoea 1 —
Adult respiratory distress syndrome 1 1
Other 2 —
Other events 2 (4) 0
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hypertension. The target BP is ⩽ 140/90 mm Hg: patients with BP
4140/90 need adjustments in their BP medication before
receiving carﬁlzomib. During carﬁlzomib administration, clinicians
should screen for and actively manage modiﬁable cardiovascular
risk factors (smoking, hypertension, diabetes, dyslipidemia and
obesity) in all patients. There are concerns that ﬂuid overload may
have a role in developing cardiovascular AEs. If poorly tolerated,
aggressive hydration may be reduced or discontinued, and signs
and symptoms of tumour lysis syndrome should be monitored.
Home BP monitoring is recommended: if BP4140/90 mm Hg,
carﬁlzomib should be temporary discontinued and hypertension
medication needs adjustments until blood pressure target
(o140/90) is reached. Future collaborative trials including
haematologists, cardiologists and regulatory agencies may clarify
how to best manage cardiovascular side effects.
We showed that treatment with wKCyd was highly effective in
elderly NDMM patients. Responses were rapid and deep, and
improved over time. During induction, 66% of patients achieved
⩾VGPR, including 30% nCR and 15% CR. During maintenance,
88% of patients achieved ⩾ VGPR, including 54% nCR and 29% CR.
Fifty percent of CR/sCR patients achieved CR/sCR during main-
tenance with a mean time to CR/sCR412 months. After a median
follow-up of 19.7 months, the 2-year PFS and OS rates were 53.2%
and 81%, respectively. The achievement of CR has been associated
with prolonged PFS and OS, also in elderly patients.30 In addition,
maintenance therapy improves outcome, and its role has been
extensively investigated.31–33The ideal treatment should combine
high response rates and continuous therapy to prolong long-term
outcome. Despite the limitations of cross-trial comparisons, the
promising antitumour activity observed with weekly carﬁlzomib in
this study was similar to—or even better than—that reported in
our prior study with twice weekly carﬁlzomib and also to the one
observed in the French phase 1/2 trial and in the CLARION trial,
both with twice weekly carﬁlzomib plus melphalan–
prednisone.20,21 The improved results with wKCyd were probably
due to the better risk/beneﬁt proﬁle and the continuous treatment
with carﬁlzomib. Nevertheless, better results were seen with
carﬁlzomib–lenalidomide–dexamethasone combination, which
induced an at least nCR rate of 62–63%, including a sCR rate of
42% and a 2-year PFS rate of 92%.34,35 The higher CR rate
observed in these patients was probably attributable to the
combination of a proteasome inhibitor and an immunomodula-
tory agent, and to the enrolment of younger patients. Indeed, in
that studies, median age was 59–60 years, with 57–58% of
patients o65 years and thus potentially transplant eligible. Of
note, the combination KCyd has the advantage of a lower cost,
providing good efﬁcacy. Furthermore, as survival continues to
improve in MM patients, it is essential to consider subsequent
treatment options when choosing therapy at diagnosis. As KCyd
regimen does not use bortezomib or lenalidomide, patients
initially treated with KCyd may still receive these other agents at
relapse.
No statistically signiﬁcant PFS difference was observed in
patients with high risk cytogenetic status compared with those
with standard risk (2-year PFS 68% versus 53%, hazard ratio 0.45,
P= 0.24). Although the number of patients in this subgroup
analysis was limited and deﬁnitive conclusions cannot be drawn,
these data are consistent with those reported in the subgroup
analysis of the ASPIRE trial. This pre-planned analysis showed that
carﬁlzomib–lenalidomide–dexamethasone in relapsed/refractory
patients improved the poor prognosis associated with high-risk
cytogenetics.36 Similar results were reported in two phase 2
studies with carﬁlzomib–lenalidomide–dexamethasone in
NDMM.34,35 These data, if conﬁrmed on a larger number of
patients, may have important implications regarding risk-adapted
therapy.
In conclusion, our study showed that in elderly patients
ineligible for transplant, the more convenient dosing schedule
wKCyd was highly effective with excellent CR rates and had an
acceptable toxicity.
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